Antibody therapies in CNS diseases

Neuropharmacology

Volumn 120, Issue , 2017, Pages 38-55

  Freskgård, Per Ola ^a   Urich, Eduard ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer's disease; Blood brain barrier; Delivery; Therapeutic antibodies

Indexed keywords

ADUCANUMAB; ALPHA4 INTEGRIN; AMYLOID BETA PROTEIN; ANGIOPEPTIN; BAPINEUZUMAB; BETA GLUCURONIDASE; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; CD20 ANTIGEN; CENTRAL NERVOUS SYSTEM AGENTS; DRUG VEHICLE; FC RECEPTOR; FOLATE RECEPTOR; FOLATE RECEPTOR 1; GANTENERUMAB; GRN 1005; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MELLANOTRANSFERRIN; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; NATALIZUMAB; NICOTINIC RECEPTOR; OCRELIZUMAB; OPICINUMAB; SMALL INTERFERING RNA; SOLANEZUMAB; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTIBODY; IMMUNOLOGIC FACTOR;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN SIZE; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; GLIOMA; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SYNAPTIC TRANSMISSION; TRANSCYTOSIS; TREATMENT INDICATION; UPREGULATION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84961771724     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.03.014     Document Type: Review

References (217)

1. AAIC. Gantenerumab Scarlet RoAD. https://www.alz.org/aaic/releases_2015/wed-7amET.asp (2015).
2. Abbott, N.J., Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis. 36 (2013), 437–449, 10.1007/s10545-013-9608-0.
3. Abbott, N.J., Ronnback, L., Hansson, E., Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7 (2006), 41–53, 10.1038/nrn1824.
4. Abulrob, A., Sprong, H., Van Bergen en Henegouwen, P., Stanimirovic, D., The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95 (2005), 1201–1214, 10.1111/j.1471-4159.2005.03463.x.
5. Alata, W., Paris-Robidas, S., Emond, V., Bourasset, F., Calon, F., Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion. Mol. Pharm. 11 (2014), 243–253, 10.1021/mp400421a.
6. Alemany, R., et al. Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. J. Cell Sci. 104:Pt 4 (1993), 1155–1162.
7. Allen, N.J., Barres, B.A., Neuroscience: Glia - more than just brain glue. Nature 457 (2009), 675–677, 10.1038/457675a.
8. Alvarez-Erviti, L., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29 (2011), 341–345, 10.1038/nbt.1807.
9. Alzforum. AD monoclonals. http://www.alzforum.org/news/conference-coverage/aducanumab-solanezumab-gantenerumab-data-lift-crenezumab-well August 10 (2015).
10. Alzforum. Aducanumab. http://www.alzforum.org/therapeutics/aducanumab March 25 (2015).
11. Arap, W., et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8 (2002), 121–127, 10.1038/nm0202-121.
12. Armulik, A., et al. Pericytes regulate the blood–brain barrier. Nature 468 (2010), 557–561, 10.1038/nature09522.
13. Bandara, N.A., Hansen, M.J., Low, P.S., Effect of receptor occupancy on folate receptor internalization. Mol. Pharm. 11 (2014), 1007–1013, 10.1021/mp400659t.
14. Banks, W.A., Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 90 (2008), 589–594, 10.1002/bip.20980.
15. Bard, F., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000), 916–919, 10.1038/78682.
16. Benchenane, K., et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111 (2005), 2241–2249, 10.1161/01.CIR.0000163542.48611.A2.
17. Bien-Ly, N., et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211 (2014), 233–244, 10.1084/jem.20131660.
18. Biogen. https://clinicaltrials.gov/ct2/show/NCT01721161?term=lingo&rank=2. (2015).
19. Birks, J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database.Syst. Rev., 2006, CD005593, 10.1002/14651858.CD005593.
20. Blanchette, M., Daneman, R., Formation and maintenance of the BBB. Mech. Dev., 2015, 10.1016/j.mod.2015.07.007.
21. Bloomgren, G., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366 (2012), 1870–1880, 10.1056/NEJMoa1107829.
22. Boado, R.J., Pardridge, W.M., Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 37 (2009), 2299–2304, 10.1124/dmd.109.028787.
23. Boado, R.J., Pardridge, W.M., Genetic engineering of IgG-glucuronidase fusion proteins. J. Drug Target 18 (2010), 205–211, 10.3109/10611860903353362.
24. Boado, R.J., Zhang, Y., Zhang, Y., Xia, C.F., Pardridge, W.M., Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug. Chem. 18 (2007), 447–455, 10.1021/bc060349x.
25. Boado, R.J., et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol. Bioeng. 99 (2008), 475–484, 10.1002/bit.21602.
26. Bressler, J., Clark, K., O'Driscoll, C., Assessing blood-brain barrier function using in vitro assays. Methods Mol. Biol. 1066 (2013), 67–79, 10.1007/978-1-62703-604-7_6.
27. Broadwell, R.D., Baker-Cairns, B.J., Friden, P.M., Oliver, C., Villegas, J.C., Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142 (1996), 47–65, 10.1006/exnr.1996.0178.
28. Brown, J.P., Woodbury, R.G., Hart, C.E., Hellstrom, I., Hellstrom, K.E., Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc. Natl. Acad. Sci. U. S. A. 78 (1981), 539–543.
29. Brownlees, J., Williams, C.H., Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem. 60 (1993), 793–803.
30. Bu, G., Maksymovitch, E.A., Geuze, H., Schwartz, A.L., Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J. Biol. Chem. 269 (1994), 29874–29882.
31. Burgess, A., Shah, K., Hough, O., Hynynen, K., Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev. Neurother. 15 (2015), 477–491, 10.1586/14737175.2015.1028369.
32. Candela, P., et al. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes. Brain Res. 1594 (2015), 15–26, 10.1016/j.brainres.2014.10.047.
33. Carlos, T.M., Dobrina, A., Ross, R., Harlan, J.M., Multiple receptors on human monocytes are involved in adhesion to cultured human endothelial cells. J. Leukoc. Biol. 48 (1990), 451–456.
34. Carman, A.J., Mills, J.H., Krenz, A., Kim, D.G., Bynoe, M.S., Adenosine receptor signaling modulates permeability of the blood-brain barrier. J. Neurosci. 31 (2011), 13272–13280, 10.1523/JNEUROSCI.3337-11.2011.
35. Ceschin, D.G., Sanchez, M.C., Chiabrando, G.A., Insulin induces the low density lipoprotein receptor-related protein 1 (LRP1) degradation by the proteasomal system in J774 macrophage-derived cells. J. Cell. Biochem. 106 (2009), 372–380, 10.1002/jcb.22014.
36. Chaudhuri, A., Behan, P.O., Natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003), 1598–1599, 10.1056/NEJM200304173481614 author reply 1598–1599.
37. Che, C., et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53 (2010), 2814–2824, 10.1021/jm9016637.
38. Chen, Y.H., Chang, M., Davidson, B.L., Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15 (2009), 1215–1218, 10.1038/nm.2025.
39. Clark, D.E., Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88 (1999), 815–821, 10.1021/js980402t.
40. Clark, A.J., Davis, M.E., Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proc. Natl. Acad. Sci. U. S. A., 2015, 10.1073/pnas.1517048112.
41. Clinical-Trials-Gov. LINGO1 monoclonal. https://clinicaltrials.gov/ct2/show/record/NCT01864148?term=lingo&rank=1 (2014).
42. Coloma, M.J., et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17 (2000), 266–274.
43. Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517, 10.1016/S0140-6736(08)61620-7.
44. Daneman, R., Zhou, L., Kebede, A.A., Barres, B.A., Pericytes are required for blood–brain barrier integrity during embryogenesis. Nature 468 (2010), 562–566, 10.1038/nature09513.
45. De Groot, A.S., et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood 112 (2008), 3303–3311, 10.1182/blood-2008-02-138073.
46. Deane, R., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43 (2004), 333–344, 10.1016/j.neuron.2004.07.017.
47. DeMattos, R.B., et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 8850–8855, 10.1073/pnas.151261398.
48. Demeule, M., et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324 (2008), 1064–1072, 10.1124/jpet.107.131318.
49. Demeule, M., et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106 (2008), 1534–1544, 10.1111/j.1471-4159.2008.05492.x.
50. Doody, R.S., Farlow, M., Aisen, P.S., Alzheimer's Disease Cooperative Study Data, A. & Publication, C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med., 370, 2014, 1460, 10.1056/NEJMc1402193.
51. Drappatz, J., et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin. Cancer Res. 19 (2013), 1567–1576, 10.1158/1078-0432.CCR-12-2481.
52. Ecker, D.M., Jones, S.D., Levine, H.L., The therapeutic monoclonal antibody market. mAbs 7 (2015), 9–14, 10.4161/19420862.2015.989042.
53. Egleton, R.D., Davis, T.P., Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18 (1997), 1431–1439.
54. El-Andaloussi, S., et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7 (2012), 2112–2126, 10.1038/nprot.2012.131.
55. Engelhardt, B., Ransohoff, R.M., Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33 (2012), 579–589, 10.1016/j.it.2012.07.004.
56. Farrington, G.K., et al. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. Faseb J. 28 (2014), 4764–4778, 10.1096/fj.14-253369.
57. Fishman, J.B., Rubin, J.B., Handrahan, J.V., Connor, J.R., Fine, R.E., Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18 (1987), 299–304, 10.1002/jnr.490180206.
58. Food, M.R., et al. Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 269 (1994), 3034–3040.
59. Food, M.R., Sekyere, E.O., Richardson, D.R., The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein. Eur. J. Biochem. 269 (2002), 4435–4445.
60. Freskgård, P.-O., Niewoehner, J., Urich, E., Time to open the blood–brain barrier gate for biologics?. Future Neurol. 9 (2015), 243–245.
61. Friden, P.M., et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 4771–4775.
62. Fu, A., Wang, Y., Zhan, L., Zhou, R., Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharm. Res. 29 (2012), 1562–1569, 10.1007/s11095-012-0667-y.
63. Gabathuler, R., Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier. Ther. Deliv. 1 (2010), 571–586.
64. Gaillard, P.J., Visser, C.C., de Boer, A.G., Targeted delivery across the blood-brain barrier. Expert Opin. Drug Deliv. 2 (2005), 299–309, 10.1517/17425247.2.2.299.
65. Gao, Y., et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain. Biomacromolecules 15 (2014), 1010–1018, 10.1021/bm401906p.
66. Garg, A., Balthasar, J.P., Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J. 11 (2009), 553–557, 10.1208/s12248-009-9129-9.
67. Goate, A., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991), 704–706, 10.1038/349704a0.
68. Gong, C., Li, X., Xu, L., Zhang, Y.H., Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials 33 (2012), 3456–3463, 10.1016/j.biomaterials.2011.12.017.
69. Gosk, S., Vermehren, C., Storm, G., Moos, T., Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow. Metab. 24 (2004), 1193–1204, 10.1097/01.WCB.0000135592.28823.47.
70. Grapp, M., et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat. Commun., 4, 2013, 2123, 10.1038/ncomms3123.
71. Griep, L.M., et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 15 (2013), 145–150, 10.1007/s10544-012-9699-7.
72. Haqqani, A.S., et al. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. Mol. Pharm. 10 (2013), 1542–1556, 10.1021/mp3004995.
73. Hardy, J., Mullan, M., Alzheimer's disease. In search of the soluble. Nature 359 (1992), 268–269, 10.1038/359268a0.
74. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356, 10.1126/science.1072994.
75. Henderson, S.J., et al. Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain 137 (2014), 553–564, 10.1093/brain/awt308.
76. Herz, J., Strickland, D.K., LRP: a multifunctional scavenger and signaling receptor. J. Clin. Investig. 108 (2001), 779–784, 10.1172/JCI13992.
77. Herz, J., Kowal, R.C., Goldstein, J.L., Brown, M.S., Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. Embo J. 9 (1990), 1769–1776.
78. Hilgenbrink, A.R., Low, P.S., Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94 (2005), 2135–2146, 10.1002/jps.20457.
79. Holm, J., Hansen, S.I., Hoier-Madsen, M., Bostad, L., High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein. Biochem. J. 280:Pt 1 (1991), 267–271.
80. Hwang, D.W., et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32 (2011), 4968–4975, 10.1016/j.biomaterials.2011.03.047.
81. Jacobsen, H., et al. Combined treatment with a BACE inhibitor and anti-Abeta antibody gantenerumab enhances amyloid reduction in APPLondon mice. J. Neurosci. 34 (2014), 11621–11630, 10.1523/JNEUROSCI.1405-14.2014.
82. Jefferies, W.A., et al. Transferrin receptor on endothelium of brain capillaries. Nature 312 (1984), 162–163.
83. Jolliffe, L.K., Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int. Rev. Immunol. 10 (1993), 241–250.
84. Jones, A.R., Shusta, E.V., Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24 (2007), 1759–1771, 10.1007/s11095-007-9379-0.
85. Jones, A.R., Stutz, C.C., Zhou, Y., Marks, J.D., Shusta, E.V., Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol. J. 9 (2014), 664–674, 10.1002/biot.201300550.
86. Kamen, B.A., Wang, M.T., Streckfuss, A.J., Peryea, X., Anderson, R.G., Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263 (1988), 13602–13609.
87. Kappos, L., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378 (2011), 1779–1787, 10.1016/S0140-6736(11)61649-8.
88. Karkan, D., et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One, 3, 2008, e2469, 10.1371/journal.pone.0002469.
89. Karran, E., Hardy, J., Antiamyloid therapy for Alzheimer's disease–are we on the right road?. N. Engl. J. Med. 370 (2014), 377–378, 10.1056/NEJMe1313943.
90. Ke, W., et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30 (2009), 6976–6985, 10.1016/j.biomaterials.2009.08.049.
91. Keaney, J., Campbell, M., The dynamic blood-brain barrier. FEBS J., 2015, 10.1111/febs.13412.
92. Kennard, M.L., Feldman, H., Yamada, T., Jefferies, W.A., Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat. Med. 2 (1996), 1230–1235.
93. Kennedy, M.D., Jallad, K.N., Lu, J., Low, P.S., Ben-Amotz, D., Evaluation of folate conjugate uptake and transport by the choroid plexus of mice. Pharm. Res. 20 (2003), 714–719.
94. Kim, D.K., et al. Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease. Neuropsychopharmacol. Offic. Publ. Am. Coll. Neuropsychopharmacol. 25 (2001), 84–90, 10.1016/S0893-133X(00)00230-X.
95. King, G.L., Johnson, S.M., Receptor-mediated transport of insulin across endothelial cells. Science 227 (1985), 1583–1586.
96. Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975), 495–497.
97. Kolonin, M.G., et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J. Offic. Publ. Fed. Am. Soc. Exp. Biol. 20 (2006), 979–981, 10.1096/fj.05-5186fje.
98. Koppers-Lalic, D., Hogenboom, M.M., Middeldorp, J.M., Pegtel, D.M., Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv. Drug Deliv. Rev. 65 (2013), 348–356, 10.1016/j.addr.2012.07.006.
99. Kumar, P., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007), 39–43, 10.1038/nature05901.
100. Kurzrock, R., et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11 (2012), 308–316, 10.1158/1535-7163.MCT-11-0566.
101. Lassmann, H., van Horssen, J., Mahad, D., Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 8 (2012), 647–656, 10.1038/nrneurol.2012.168.
102. Lee, R.J., Wang, S., Low, P.S., Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim. Biophys. Acta 1312 (1996), 237–242.
103. Lee, H.J., Engelhardt, B., Lesley, J., Bickel, U., Pardridge, W.M., Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 292 (2000), 1048–1052.
104. Lentz, T.L., Rabies virus binding to an acetylcholine receptor alpha-subunit peptide. J. Mol. Recognit. JMR 3 (1990), 82–88, 10.1002/jmr.300030205.
105. Lentz, T.L., Burrage, T.G., Smith, A.L., Crick, J., Tignor, G.H., Is the acetylcholine receptor a rabies virus receptor?. Science 215 (1982), 182–184.
106. Leybaert, L., De Bock, M., Van Moorhem, M., Decrock, E., De Vuyst, E., Neurobarrier coupling in the brain: adjusting glucose entry with demand. J. Neurosci. Res. 85 (2007), 3213–3220, 10.1002/jnr.21189.
107. Liddelow, S., Barres, B., SnapShot: astrocytes in health and disease. Cell, 162, 2015, 10.1016/j.cell.2015.08.029 1170–1170 e1171.
108. Lillis, A.P., Van Duyn, L.B., Murphy-Ullrich, J.E., Strickland, D.K., LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88 (2008), 887–918, 10.1152/physrev.00033.2007.
109. Lilly E. https://clinicaltrials.gov/ct2/show/NCT00905372?term=solanezumab&rank=5. (2014).
110. Lippmann, E.S., et al. Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30 (2012), 783–791, 10.1038/nbt.2247.
111. Liu, Y., et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30 (2009), 4195–4202, 10.1016/j.biomaterials.2009.02.051.
112. Llorens, F., Gil, V., del Rio, J.A., Emerging functions of myelin-associated proteins during development, neuronal plasticity, and neurodegeneration. Faseb J. 25 (2011), 463–475, 10.1096/fj.10-162792.
113. Lu, J.Z., Hui, E.K., Boado, R.J., Pardridge, W.M., Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. Bioconjug. Chem. 21 (2010), 151–156, 10.1021/bc900382q.
114. Lyck, R., et al. Culture-induced changes in blood–brain barrier transcriptome: implications for amino-acid transporters in vivo. J. Cereb. Blood Flow Metab. 29 (2009), 1491–1502, 10.1038/jcbfm.2009.72.
115. Magliozzi, R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130 (2007), 1089–1104, 10.1093/brain/awm038.
116. Majumdar, S., Siahaan, T.J., Peptide-mediated targeted drug delivery. Med. Res. Rev. 32 (2012), 637–658, 10.1002/med.20225.
117. Maletinska, L., et al. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 60 (2000), 2300–2303.
118. Manich, G., et al. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice. Eur. J. Pharm. Sci. Offic. J. Eur. Fed. Pharm. Sci. 49 (2013), 556–564, 10.1016/j.ejps.2013.05.027.
119. May, P., Reddy, Y.K., Herz, J., Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J. Biol. Chem. 277 (2002), 18736–18743, 10.1074/jbc.M201979200.
120. Mi, S., et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 7 (2004), 221–228, 10.1038/nn1188.
121. Mi, S., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13 (2007), 1228–1233, 10.1038/nm1664.
122. Miller, D.S., Regulation of ABC transporters at the blood-brain barrier. Clin. Pharmacol. Ther. 97 (2015), 395–403, 10.1002/cpt.64.
123. Miller, D.H., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003), 15–23, 10.1056/NEJMoa020696.
124. Montagne, A., et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85 (2015), 296–302, 10.1016/j.neuron.2014.12.032.
125. Moos, T., Morgan, E.H., Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J. Neurochem. 79 (2001), 119–129.
126. Morgan, D., Mechanisms of A beta plaque clearance following passive A beta immunization. Neuro-degener. Dis. 2 (2005), 261–266, 10.1159/000090366.
127. Moroo, I., et al. Identification of a novel route of iron transcytosis across the mammalian blood-brain barrier. Microcirculation 10 (2003), 457–462, 10.1038/sj.mn.7800213.
128. Muruganandam, A., Tanha, J., Narang, S., Stanimirovic, D., Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. Offic. Publ. Fed. Am. Soc. Exp. Biol. 16 (2002), 240–242, 10.1096/fj.01-0343fje.
129. Nakamasu, K., et al. Membrane-bound transferrin-like protein (MTf): structure, evolution and selective expression during chondrogenic differentiation of mouse embryonic cells. Biochim. Biophys. Acta 1447 (1999), 258–264.
130. Neuwelt, E.A., et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 12 (2011), 169–182, 10.1038/nrn2995.
131. Niewoehner, J., et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81 (2014), 49–60, 10.1016/j.neuron.2013.10.061.
132. Ormazabal, A., et al. Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of paediatric patients: reference values for a paediatric population. Clin. Chim. Acta Int. J. Clin. Chem. 371 (2006), 159–162, 10.1016/j.cca.2006.03.004.
133. Ostrowitzki, S., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69 (2012), 198–207, 10.1001/archneurol.2011.1538.
134. Palmiotti, C.A., et al. In vitro cerebrovascular modeling in the 21st century: current and prospective technologies. Pharm. Res. 31 (2014), 3229–3250, 10.1007/s11095-014-1464-6.
135. Pan, W., et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117 (2004), 5071–5078, 10.1242/jcs.01381.
136. Pardridge, W.M., Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 1 (2002), 131–139, 10.1038/nrd725.
137. Pardridge, W.M., Drug targeting to the brain. Pharm. Res. 24 (2007), 1733–1744, 10.1007/s11095-007-9324-2.
138. Pardridge, W.M., Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 19 (2008), 1327–1338, 10.1021/bc800148t.
139. Pardridge, W.M., Boado, R.J., Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 503 (2012), 269–292, 10.1016/B978-0-12-396962-0.00011-2.
140. Pardridge, W.M., Eisenberg, J., Yang, J., Human blood-brain barrier transferrin receptor. Metabolism 36 (1987), 892–895.
141. Pardridge, W.M., Triguero, D., Yang, J., Cancilla, P.A., Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J. Pharmacol. Exp. Ther. 253 (1990), 884–891.
142. Pardridge, W.M., Kang, Y.S., Buciak, J.L., Yang, J., Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12 (1995), 807–816.
143. Paris-Robidas, S., Emond, V., Tremblay, C., Soulet, D., Calon, F., In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 80 (2011), 32–39, 10.1124/mol.111.071027.
144. Patsch, C., et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat. Cell Biol. 17 (2015), 994–1003, 10.1038/ncb3205.
145. Pepinsky, R.B., et al. Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration. J. Pharmacol. Exp. Ther. 339 (2011), 519–529, 10.1124/jpet.111.183483.
146. PharmaBiotech. In Jain PharmaBiotech (2010).
147. Poduslo, J.F., Curran, G.L., Berg, C.T., Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 5705–5709.
148. Qiu, C., Kivipelto, M., von Strauss, E., Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 11 (2009), 111–128.
149. Quinn, K.A., et al. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J. Biol. Chem. 272 (1997), 23946–23951.
150. Rajotte, D., et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Investig. 102 (1998), 430–437, 10.1172/JCI3008.
151. Reardon, S., Antibody drugs for Alzheimer's show glimmers of promise. Nature 523 (2015), 509–510, 10.1038/nature.2015.18031.
152. Regina, A., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155 (2008), 185–197, 10.1038/bjp.2008.260.
153. Regina, A., et al. ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol. Cancer Ther. 14 (2015), 129–140, 10.1158/1535-7163.MCT-14-0399.
154. Reichert, J.M., Which are the antibodies to watch in 2013?. mAbs 5 (2013), 1–4, 10.4161/mabs.22976.
155. Reisberg, B., et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 (2003), 1333–1341, 10.1056/NEJMoa013128.
156. Reynolds, E.H., Gallagher, B.B., Mattson, R.H., Bowers, M., Johnson, A.L., Relationship between serum and cerebrospinal fluid folate. Nature 240 (1972), 155–157.
157. Richardson, D.R., Morgan, E.H., The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta 1690 (2004), 124–133, 10.1016/j.bbadis.2004.06.002.
158. Ridgway, J.B., Presta, L.G., Carter, P., 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9 (1996), 617–621.
159. Roche, Roche's Ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus Interferon Beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis. 2015 http://www.roche.com/media/store/releases/med-cor-2015-06-30.htm.
160. Roche, Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study. 2015 http://www.roche.com/investors/updates/inv-update-2015-09-28.htm.
161. Rodriguez, A., Tatter, S.B., Debinski, W., Neurosurgical techniques for disruption of the blood-brain barrier for glioblastoma treatment. Pharmaceutics 7 (2015), 175–187, 10.3390/pharmaceutics7030175.
162. Rothenberger, S., et al. Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium. Brain Res. 712 (1996), 117–121.
163. Rubenstein, J.L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25 (2007), 1350–1356, 10.1200/JCO.2006.09.7311.
164. Sade, H., et al. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS One, 9, 2014, e96340, 10.1371/journal.pone.0096340.
165. Salloway, S., Sperling, R., Brashear, H.R., Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med., 370, 2014, 1460.
166. Schenk, D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999), 173–177, 10.1038/22124.
167. Shen, J., et al. Poly(ethylene glycol)-block-poly(D,L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J. Drug Target 19 (2011), 197–203, 10.3109/1061186X.2010.483517.
168. Shi, N., Boado, R.J., Pardridge, W.M., Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18 (2001), 1091–1095.
169. Siemers, E.R., et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33 (2010), 67–73, 10.1097/WNF.0b013e3181cb577a.
170. Siemers, E.R., et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement., 2015, 10.1016/j.jalz.2015.06.1893.
171. Son, S., et al. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. J. Control Release 155 (2011), 18–25, 10.1016/j.jconrel.2010.08.011.
172. Sorensen, P.S., et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 82 (2014), 573–581, 10.1212/WNL.0000000000000125.
173. Sospedra, M., Martin, R., Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005), 683–747, 10.1146/annurev.immunol.23.021704.115707.
174. Spiegelberg, H.L., Biological role of different antibody classes. Int. Arch. Allergy Appl. Immunol. 90:Suppl. 1 (1989), 22–27.
175. St-Amour, I., et al. Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J. Cereb. Blood Flow. Metab. 33 (2013), 1983–1992, 10.1038/jcbfm.2013.160.
176. Stewart, P.A., Endothelial vesicles in the blood-brain barrier: are they related to permeability?. Cell. Mol. Neurobiol. 20 (2000), 149–163.
177. Stuve, O., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59 (2006), 743–747, 10.1002/ana.20858.
178. Sui, Y.T., Bullock, K.M., Erickson, M.A., Zhang, J., Banks, W.A., Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides 62 (2014), 197–202, 10.1016/j.peptides.2014.09.018.
179. Suryo Rahmanto, Y., Bal, S., Loh, K.H., Yu, Y., Richardson, D.R., Melanotransferrin: search for a function. Biochim. Biophys. Acta 1820 (2012), 237–243, 10.1016/j.bbagen.2011.09.003.
180. Svenningsson, A., et al. Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol.(R) Neuroimmunol. Neuroinflamm., 2, 2015, e79, 10.1212/NXI.0000000000000079.
181. Tamaki, C., Ohtsuki, S., Terasaki, T., Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol. Pharmacol. 72 (2007), 850–855, 10.1124/mol.107.036913.
182. Tang, Y., et al. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther. 14 (2007), 523–532, 10.1038/sj.gt.3302888.
183. Thomsen, L.B., Burkhart, A., Moos, T., A triple culture model of the blood-brain barrier using porcine brain endothelial cells, astrocytes and pericytes. PLoS One, 10, 2015, e0134765, 10.1371/journal.pone.0134765.
184. Tietz, S., Engelhardt, B., Brain barriers: crosstalk between complex tight junctions and adherens junctions. J. Cell Biol. 209 (2015), 493–506, 10.1083/jcb.201412147.
185. Tiller, K.E., Tessier, P.M., Advances in antibody design. Annu. Rev. Biomed. Eng., 2015, 10.1146/annurev-bioeng-071114-040733.
186. Tran, J.Q., et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol.(R) Neuroimmunol. Neuroinflamm., 1, 2014, e18, 10.1212/NXI.0000000000000018.
187. Turek, J.J., Leamon, C.P., Low, P.S., Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell Sci. 106:Pt 1 (1993), 423–430.
188. Underwood, E., Alzheimer's amyloid theory gets modest boost. Science, 349, 2015, 464, 10.1126/science.349.6247.464 Neuroscience.
189. Urich, E., Lazic, S.E., Molnos, J., Wells, I., Freskgard, P.O., Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One, 7, 2012, e38149, 10.1371/journal.pone.0038149.
190. Urich, E., et al. Multicellular self-assembled spheroidal model of the blood brain barrier. Sci. Rep., 3, 2013, 1500, 10.1038/srep01500.
191. Urich, E., et al. Cargo delivery into the brain by in vivo identified transport peptides. Sci. Rep., 5, 2015, 14104, 10.1038/srep14104.
192. van Rooy, I., et al. Identification of peptide ligands for targeting to the blood-brain barrier. Pharm. Res. 27 (2010), 673–682, 10.1007/s11095-010-0053-6.
193. Walker, J.R., et al. Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J. Neurosci. 33 (2013), 2457–2464, 10.1523/JNEUROSCI.3407-12.2013.
194. Walsh, G., Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32 (2014), 992–1000, 10.1038/nbt.3040.
195. Wan, X.M., Chen, Y.P., Xu, W.R., Yang, W.J., Wen, L.P., Identification of nose-to-brain homing peptide through phage display. Peptides 30 (2009), 343–350, 10.1016/j.peptides.2008.09.026.
196. Wang, H.X., et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 56 (2001), 1188–1194.
197. Weber, M.S., Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS?. Neurol.(R) Neuroimmunol. Neuroinflamm., 2, 2015, e84, 10.1212/NXI.0000000000000084.
198. Weitman, S.D., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 52 (1992), 3396–3401.
199. Wiley, D.T., Webster, P., Gale, A., Davis, M.E., Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 8662–8667, 10.1073/pnas.1307152110.
200. Wilhelm, I., Krizbai, I.A., In vitro models of the blood-brain barrier for the study of drug delivery to the brain. Mol. Pharm. 11 (2014), 1949–1963, 10.1021/mp500046f.
201. Winkler, E.A., Sengillo, J.D., Bell, R.D., Wang, J., Zlokovic, B.V., Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J. Cereb. Blood Flow. Metab. 32 (2012), 1841–1852, 10.1038/jcbfm.2012.113.
202. Winkler, E.A., et al. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125 (2013), 111–120, 10.1007/s00401-012-1039-8.
203. Witt, K.A., Gillespie, T.J., Huber, J.D., Egleton, R.D., Davis, T.P., Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22 (2001), 2329–2343.
204. Wolff, A., Antfolk, M., Brodin, B., Tenje, M., Vitro blood-brain barrier models-an overview of established models and new microfluidic approaches. J. Pharm. Sci. 104 (2015), 2727–2746, 10.1002/jps.24329.
205. Wollack, J.B., et al. Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model. J. Neurochem. 104 (2008), 1494–1503, 10.1111/j.1471-4159.2007.05095.x.
206. Work, L.M., et al. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol. Ther. 13 (2006), 683–693, 10.1016/j.ymthe.2005.11.013.
207. Wu, D., Yang, J., Pardridge, W.M., Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Investig. 100 (1997), 1804–1812, 10.1172/JCI119708.
208. Xiang, Y., et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol. 130 (2015), 487–499, 10.1007/s00401-015-1477-1.
209. Xin, H., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32 (2011), 4293–4305, 10.1016/j.biomaterials.2011.02.044.
210. Yamamoto, M., et al. Increased expression of low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor in human malignant astrocytomas. Cancer Res. 57 (1997), 2799–2805.
211. Yang, J., Chen, H., Vlahov, I.R., Cheng, J.X., Low, P.S., Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 321 (2007), 462–468, 10.1124/jpet.106.117648.
212. Yoshikawa, T., Pardridge, W.M., Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263 (1992), 897–903.
213. Yu, Y.J., et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med., 3, 2011, 84ra44, 10.1126/scitranslmed.3002230.
214. Zhang, Y., Pardridge, W.M., Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J. Neuroimmunol. 114 (2001), 168–172.
215. Zhang, Y., et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34 (2014), 11929–11947, 10.1523/JNEUROSCI.1860-14.2014.
216. Zlokovic, B.V., Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm. Res. 12 (1995), 1395–1406.
217. Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008), 178–201, 10.1016/j.neuron.2008.01.003.